CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology ...
Objectives In Breakfree-1 (NCT05869955), BMS-986353 (CD19 NEX-T®), a CD19-directed CAR T cell therapy, showed promising early safety and efficacy in severe, refractory SLE. We report updated data for ...
WILMINGTON, Mass., February 25, 2026--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has signed definitive agreements to sell certain European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results